Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genesis Technology Group Retains CCG Elite (China)

This article was originally published in PharmAsia News

Executive Summary

Genesis Technology Group Inc., one of China's top drug-makers, has retained the services of CCG Elite. Genesis hopes CCG will help it expand investor interest in the company. Genesis works with its subsidiary Lauyang Jiangbo Biotech Technologies Co. to develop and produce a number of drugs. Currently, its pipeline includes both Western drugs and traditional Chinese medicines. This year Genesis has seen total sales of $76.2 million, up a staggering 55 percent from 2006. As one of the largest non-state-owned pharmaceutical companies in China, Genesis is in an excellent position to access the country's fast-growing drug market. Experts expect the market to grow by over 13 percent in the next few years, reaching $51 billion by 2010. (Click here for more

You may also be interested in...

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee

Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts